Anti-Human Deoxycytidine Kinase (dCK) Monoclonal Antibody
Tech ID: 22470 / UC Case 2012-031-0
Background
dCK is an enzyme required for the phosphorylation of various deoxyribonucleosides and their nucleoside analogs. Deficiency of dCK has been shown to be associated with resistance to anticancer chemotherapeutic drugs (e.g. gemcitabine). dCK also has a known importance in the development of adaptive immune responses.
Applications
- The anti-human dCK monoclonal antibody allows physicians and researchers to study and detect dCK in patient samples. The mAb can be used for western blotting, immunoprecipitation, and immunohistochemistry of primary human tissue
Contact
- UCLA Technology Development Group
- ncd@tdg.ucla.edu
- tel: View Phone Number.
Inventors
- Witte, Owen N.
Other Information
Keywords
antibody, monoclonal antibody, dCK, human deoxycytidine kinase, immunohistochemistry, immunology, chemotherapy, anti-metabolites, gemcitabine, cancer, pancreatic cancer, breast cancer, ovarian cancer, lung cancer
Categorized As
Additional Technologies by these Inventors
- Nucleic Acid Tetramers For High Efficiency Multiplexed Cell Sorting
- Mouse Model Deficient for the Proton Sensing Gpcr T-cell Death-associated Gene 8 (tdag)
- Novel Non-Immunogenic Positron Emission Tomography Gene Reporter
- Targeted Mass Spectrometry Approaches To Detect Kinase Pathways For Personalized Medicine
- G2A GPCR Deficient Mouse Model and G2A Monoclonal Antibody
- Proton-sensing G Protein-coupled Receptor 4 Knockout
- Derivation Of A Human Neuroendocrine Prostate Cancer Cell Line With Defined Oncogenic Drivers
- Novel Polyclonal Antibody to Detect a Bruton's Tyrosine Kinase Phosphorylation Site
- Non-Immunogenic Positron Emission Tomography Gene Reporter Systems
